Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
AstraZeneca
Colorcon
Medtronic
McKesson

Last Updated: March 29, 2020

DrugPatentWatch Database Preview

ROXYBOND Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

US ANDA Litigation and Generic Entry Outlook for Roxybond

A generic version of ROXYBOND was approved as oxycodone hydrochloride by ACTAVIS ELIZABETH on February 6th, 2004.

  Start Trial

Summary for ROXYBOND
Drug patent expirations by year for ROXYBOND
Recent Litigation for ROXYBOND

Identify potential future generic entrants

District Court Litigation
Case NameDate
INSPIRION DELIVERY SCIENCES, LLC v. TEVA PHARMACEUTICALS USA, INC.2019-04-19

See all ROXYBOND litigation

US Patents and Regulatory Information for ROXYBOND

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Inspirion Delivery ROXYBOND oxycodone hydrochloride TABLET;ORAL 209777-001 Apr 20, 2017 DISCN No No   Start Trial   Start Trial Y   Start Trial
Inspirion Delivery ROXYBOND oxycodone hydrochloride TABLET;ORAL 209777-003 Apr 20, 2017 DISCN No No   Start Trial   Start Trial Y   Start Trial
Inspirion Delivery ROXYBOND oxycodone hydrochloride TABLET;ORAL 209777-002 Apr 20, 2017 DISCN No No   Start Trial   Start Trial Y   Start Trial
Inspirion Delivery ROXYBOND oxycodone hydrochloride TABLET;ORAL 209777-003 Apr 20, 2017 DISCN No No   Start Trial   Start Trial Y   Start Trial
Inspirion Delivery ROXYBOND oxycodone hydrochloride TABLET;ORAL 209777-001 Apr 20, 2017 DISCN No No   Start Trial   Start Trial Y   Start Trial
Inspirion Delivery ROXYBOND oxycodone hydrochloride TABLET;ORAL 209777-001 Apr 20, 2017 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ROXYBOND

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1685839 92292 Luxembourg   Start Trial PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
AstraZeneca
Colorcon
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.